Chen Fang's incident was just a small episode
With Chen Xia's strong rise, the people around him also prospered. Qingfeng Village underwent earth-shaking changes, and the fate of many people was changed.
However, Chen Xia did not understand the negative problems brought about by the sudden wealth of the poor before, so this time he decided to take advantage of the New Year period to sort them out.
Money is a good thing, but it can also be a bad thing.
I wonder if Chen Xia will one day regret founding the Four Seasons Group, regret having so much money, and then say that his happiest days were when he earned more than 100 yuan a month at Yuezhou Hospital?
Chen Xia, who thinks money is a bad thing, will be busy making money in the next few days.
Oh, man!
The news that Four Seasons Group decided to open up its patents for five antibiotics spread across the world in an instant following the announcement by the World Health Organization.
Now, pharmaceutical companies big and small from all over the world have gathered in Hong Kong.
The WHO has taken a very long-term view in that their requirement is to distribute the number of pharmaceutical companies that are granted patents by “continent”.
Look at the patent licensing that Chen Xia did in the past. His approach was to arrange a leading pharmaceutical company in each continent, and then everyone formed a price alliance together.
After obtaining patent authorization, major pharmaceutical companies only circulate and sell the drugs they produce within their own continents, and promise each other not to infringe on each other's markets in order to maintain high prices and high profits.
The fact is indeed as Chen Xia expected. This "alliance" formed by the four pharmaceutical companies, Pumpkin Vine Pharmaceuticals, Pfizer, Takeda Pharmaceuticals, and GlaxoSmithKline, has achieved huge success.
Each company's sales exceeded 10 billion, and its profits reached an astonishing 7 billion US dollars or more.
At the same time, Chen Xia also leveraged the connections and relationships of these three pharmaceutical giants to quickly build Four Seasons Group into a "giant."
By investing in three major pharmaceutical companies, he achieved a situation where you are in me and I am in you, and truly turned the four companies into an "interest group."
Of course, the WHO has seen this drawback, so they have decided to allocate seats by continent to target this "interest group."
This will give small and medium-sized pharmaceutical companies a chance to succeed.
For example, no matter how powerful Pfizer is in North America, I also have three quotas in Africa, and you can't control me. Then the opportunity comes for my small pharmaceutical companies in Africa.
The WHO not only wants to support small and medium-sized pharmaceutical companies and break the monopoly of "unicorn groups",
At the same time, there is another purpose, which is that if more pharmaceutical companies are authorized, there will be more competition, prices can be lowered, and more people can benefit.
Unfortunately, the WHO worked so hard to obtain the public authorization of the patent from Four Seasons Group through coercion and inducement, but will it be satisfied with the result?
Look at pumpkin vine medicine.
Didn't Chen Xia think that if he controlled the patent himself, he could produce, export, and sell the products himself and earn more profits?
But do you have this "channel"?
After you produce your medicine, you need to distribute it to hospitals, pharmacies and other sales outlets in various regions. This requires a strong and efficient logistics network, as well as a large number of "medical representatives" to promote it.
Given these conditions, it is definitely not something that a small factory or one person can handle.
If you don’t have the channels, you won’t have the ability to distribute your products across the board. So what if you have patents?
Do you have any sales channels in your own country?
If you want to export abroad, do you have a social network that can help you pass the review and approval of other countries' health and drug regulatory authorities?
At the beginning, Pumpkin Vine did not have this "channel" and had no way to enter those developed countries, so it could only earn patent fees and dividends through cooperation.
If even pumpkin vines can’t do it, how can those African and South American pharmaceutical companies do it?
So in the end, the big pharmaceutical companies control all sales channels and still have an absolute monopoly position. At most, they can only give these small pharmaceutical companies a little bit of profit.
This is why “the strong get stronger.”
The WHO's wishes are good and its ideals are hopeful, but unfortunately the reality is harsh.
Why does Chen Xia attach particular importance to "channels"?
Longfeng Pharmacy, Watsons, ParknShop Supermarket, Fortress Electrical Appliances, Four Seasons Cinema, Yuezhou Small Commodity City, Clothing City, Light Textile City, etc., even the newly built "Four Seasons Center", which one is not a "channel"?
This is the reason. If you want to sell your products without being controlled by others, you must have your own channels.
The slogan "channel is king" will never go out of date.
In the large conference room on the 38th floor of the Four Seasons Group headquarters building in Central, Hong Kong.
The Four Seasons Group's antibiotic patent licensing bidding conference was held here, and the World Health Organization also sent representatives to participate in the bidding conference.
The bidding rules are very simple. Each continent has 3 quotas.
Among them, Pumpkin Vine Pharmaceutical's three allies: Pfizer, Takeda, and GlaxoSmithKline naturally have a quota. This is to take care of their own people, and they got it according to the previous patent fees.
As for other pharmaceutical companies, the patent fee starts at 5%. Everyone bids together, and whoever offers the highest patent fee will get this precious spot.
It must be valuable because the application market of antibiotics is so vast.
It is needed for most diseases in every department, including internal medicine, surgery, pediatrics, and ENT.
From a clinical perspective, the application of this latest and excellent antibiotic can save countless lives, and life is priceless.
From the perspective of pharmaceutical companies, the more clinical use a drug has, the higher the sales volume and the higher the profit. This is not comparable to gastritis and cold medicines, or anti-rejection drugs.
This chapter is not over yet, please click on the next page to continue reading!
Continue read on readnovelmtl.com
